Patent US6176842B1 successfully refreshed from Google Patents.
US6176842B1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Ultrasound assembly for use with light activated drugs
Assignee: Ekos LLC
•
Filing: 1998-09-21
•
Granted: 2001-01-23
•
Expires: 2018-09-21
Abstract
Abstract A kit and method for causing tissue death within a tissue site is disclosed. The kit includes a media with a light activated drug activatable upon exposure to a particular level of ultrasound energy. The kit also includes a catheter with a lumen coupled with a media delivery port through which the light activated drug can be locally delivered to the tissue site. The ultrasound transducer is configured to transmit the level of ultrasound energy which activates the light activated drug with sufficient power that the ultrasound energy can penetrate the tissue site.
Inventors
- 👤 Katsuro Tachibana
- 👤 Shunro Tachibana
- 👤 James R. Anderson
- 👤 Gary Lichttenegger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 03:17
CPC Classifications
A; A61; A61K; A61K41/00; A61K41/0047; A61M; A61M37/00; A61M37/0092; A61N; A61N7/00; A61B; A61B17/00; A61B17/22; A61B17/22004; A61B17/22012; A61B17/2202; A61B2017/00831; A61B2017/00853; A61B2017/22001; A61B2017/22002; A61B2017/22021; A61B2017/22051; A61B2017/22062; A61B2017/22082; A61B2017/22088
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
139 words
A kit for causing tissue death within a tissue site, comprising: a media including a light activated drug activatable upon exposure to a sufficient level of ultrasound energy; and a catheter having an elongated catheter body with at least one axial lumen therethrough, the catheter comprising, at least one ultrasound assembly coupled to the elongated catheter body, comprising at least one ultrasound transducer coupled to an energy source, wherein the at least one ultrasound transducer generates the sufficient level of ultrasound energy; at least one temperature sensor located adjacent to the at least one ultrasound transducer, wherein the at least one temperature sensor provides a measurement of a temperature adjacent to the at least one ultrasound transducer; and at least one media delivery port in fluid communication with the at least one axial lumen for delivery of the media.
Claim 2
Dependent Claim
139 words
A kit for causing tissue death within a tissue site, comprising: a media including a light activated drug activatable upon exposure to a sufficient level of ultrasound energy; and a catheter having an elongated catheter body with at least one axial lumen therethrough, the catheter comprising, at least one ultrasound assembly coupled to the elongated catheter body, comprising at least one ultrasound transducer coupled to an energy source, wherein the at least one ultrasound transducer generates the sufficient level of ultrasound energy; at least one temperature sensor located adjacent to the at least one ultrasound transducer, wherein the at least one temperature sensor provides a measurement of a temperature adjacent to the at least one ultrasound transducer; and at least one media delivery port in fluid communication with the at least one axial lumen for delivery of the media.
Claim 3
Dependent Claim
59 words
The kit of claim 1 , further comprising a feedback control system coupled to the at least one temperature sensor, wherein the feedback control system monitors the measurement of the temperature adjacent to the at least one transducer and adjusts an output of the energy source as necessary to maintain the temperature adjacent to the transducer within predetermined boundaries.
Claim 4
Dependent Claim
79 words
The kit of claim 1 , wherein the at least one ultrasound assembly is positioned about a circumference of the elongated catheter body, and wherein the catheter further comprises at least one support member in contact with an outer circumference of the elongated catheter body, the at least one support member supporting the at least one ultrasound transducer so as to define a chamber between the at least one transducer and the outer circumference of the elongated catheter body.
Claim 5
Dependent Claim
36 words
The kit of claim 3 , wherein the chamber is filled with a media that absorbs ultrasound energy such that a transmission of ultrasound energy from the ultrasound transducer to the elongated catheter body is reduced.
Claim 6
Dependent Claim
22 words
The kit of claim 4 , wherein the media is a gas selected from a group including helium, argon, air and nitrogen.
Claim 7
Dependent Claim
21 words
The kit of claim 4 , wherein the media is a solid media selected from a group including silicon and rubber.
Claim 8
Dependent Claim
15 words
The kit of claim 3 , wherein the chamber is evacuated using a negative pressure.
Claim 9
Dependent Claim
70 words
The kit of claim 1 , wherein the catheter further comprises: a balloon positioned about the circumference of the elongated catheter body; at least one media delivery port in fluid communication with the at least one axial lumen for delivery of an expansion media to expand the balloon; and at least one media delivery port in fluid communication with the at least one axial lumen for delivery of a medicament.
Claim 10
Dependent Claim
15 words
The kit of claim 8 , wherein the balloon is positioned about the ultrasound assembly.
Claim 11
Dependent Claim
24 words
The kit of claim 8 , wherein the balloon is positioned about the circumference of the elongated catheter body adjacent to the ultrasound assembly.
Claim 12
Dependent Claim
11 words
The kit of claim 1 , wherein the media includes microbubbles.
Claim 13
Dependent Claim
11 words
The kit of claim 11 , wherein the microbubbles are liposomes.
Claim 14
Dependent Claim
24 words
The kit of claim 1 , wherein the media includes an emulsion with a lipoid as a hydrophobic phase dispersed in a hydrophilic phase.
Claim 15
Dependent Claim
29 words
The kit of claim 1 , wherein the light activated drug is coupled with a site directing molecule which has an affinity for an element of the tissue site.
Claim 16
Dependent Claim
14 words
The kit of claim 14 , wherein the site directing molecule is a oligonucleotide.
Claim 17
Dependent Claim
28 words
The kit of claim 1 , wherein the light activated drug is selected from the group consisting of GdT2BET, LuT2BET, SnEt 2 and T2B1 TXP Metal Complex-Oligonuleotide Conjugate.
Claim 18
Dependent Claim
24 words
The kit of claim 1 , wherein the light activated drug is selected from the group including photoreactive pyrrole-derived macrocycles and expanded pyrrole-based macrocycles.
Claim 19
Dependent Claim
55 words
The kit of claim 1 , wherein the light activated drug is selected from the group consisting of porphyrins, chlorins, bacteriochlorins, isobateriochlorins, phthalocyanines, naphtalocyanines, porphycenes, sapphyrins, texaphyrins, derivatives of porphyrins, derivatives of chlorins, derivatives of bacteriochlorins, derivatives of isobateriochlorins, derivatives of phthalocyanines, derivatives of naphtalocyanines, derivatives of porphycenes, derivatives of sapphyrins and derivatives of texaphyrins.
Claim 20
Dependent Claim
15 words
The kit of claim 1 , wherein the light activated drug includes a green porphyrin.
Claim 21
Dependent Claim
28 words
The kit of claim 1 , wherein the ultrasound transducer is configured to deliver ultrasound energy of approximately 0.3 W/cm 2 at a frequency of approximately 1.3 MHz.
References Cited (Backward Citations)
US3433226A
Cited
US4027659A
Cited
US4040414A
Cited
US4319580A
Cited
US4354502A
Cited
US4512762A
Cited
US4531943A
Cited
US4917088A
Cited
US4750902A
Cited
US4955863A
Cited
US4767402A
Cited
US4808153A
Cited
US4780212A
Cited
WO1989004142A1
Cited
US4870953A
Cited
US4971991A
Cited
US5163421A
Cited
US4992257A
Cited
US5421338A
Cited
US4924863A
Cited
US5158071A
Cited
US4877031A
Cited
US5344435A
Cited
US4920954A
Cited
DE3919592A1
Cited
US4917102A
Cited
US5021044A
Cited
US5599923A
Cited
US5567687A
Cited
US5328470A
Cited
US4936281A
Cited
US5594136A
Cited
US5770222A
Cited
WO1991009629A1
Cited
DE4005743A1
Cited
US5323769A
Cited
US5190766A
Cited
US5498238A
Cited
US5628730A
Cited
US5282785A
Cited
US5286254A
Cited
US5197946A
Cited
US5520189A
Cited
US5660180A
Cited
US5149319A
Cited
US5250034A
Cited
WO1992007622A1
Cited
US5269291A
Cited
US5431663A
Cited
US5267954A
Cited
US5474530A
Cited
US5304115A
Cited
US5447509A
Cited
US5353798A
Cited
US5445155A
Cited
US5458568A
Cited
EP0529675A2
Cited
US5363853A
Cited
US5345940A
Cited
US5632970A
Cited
US5465726A
Cited
US5380273A
Cited
US5295484A
Cited
US5327891A
Cited
EP0629382A1
Cited
WO1994005361A1
Cited
US5362309A
Cited
US5474531A
Cited
US5318014A
Cited
US5617851A
Cited
US5354279A
Cited
US5620479A
Cited
US5603327A
Cited
US5267985A
Cited
WO1995001751A1
Cited
US5390678A
Cited
US5489279A
Cited
US5423797A
Cited
US5514092A
Cited
US5509896A
Cited
US5695460A
Cited
US5663327A
Cited
WO1996027341A1
Cited
WO1996029935A1
Cited
US5616342A
Cited
US5606974A
Cited
WO1996035469A1
Cited
WO1996036286A1
Cited
US5707608A
Cited
US5618275A
Cited
US5735811A
Cited
US5725494A
Cited
US5846218A
Cited
WO1998011826A1
Cited
WO1998048711A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2004-01-23 | 2004-07-24 | 2005-01-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2008-01-23 | 2008-07-24 | 2009-01-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2012-01-23 | 2012-07-24 | 2013-01-23 | $7700.00 | Window Closed / Lapsed |